BPC-157

The non-clinical literature is dominated by rodent work: the FDA counted 24 articles describing in vivo and in vitro models, largely in Wistar rats, covering surgically created colonic fistulas, transected tendons, gastrointestinal and hepatic lesions, and rodent models of stroke, encephalopathy and spinal cord injury. Human data exist but are very thin. The FDA identified five clinical studies, of which the only randomised controlled one is a meeting abstract describing 53 subjects with mild to moderate ulcerative colitis randomised to an 80 mg enema or placebo for two weeks, with 46 completers and a between-group disease activity difference of 1.6 points on a confidence interval spanning zero. One phase 1 study is registered and one phase 2 study in acute hamstring strain began recruiting on 2 February 2026 with no results posted. In two rectal studies the compound was not detected in plasma.

What is not established

There is no established human pharmacokinetic profile by any route other than rectal, and no published full-text randomised controlled study for any indication. The FDA judged both the free base and the acetate not well characterised physically and chemically, citing absent data on peptide-related impurities, aggregates, bioburden, bacterial endotoxins and particle size.

What distinguishes BPC-157

The name is a common name rather than an adopted one, and the FDA records encountering multiple salts and derivatives with DIFFERENT active moieties sold commercially under that single name, which the agency states is itself a safety risk because a buyer may receive a different substance from the one specified. The compound is described in the literature only as a pentadecapeptide fragment of body protection compound, a protein reported from gastric juice in 1993, so its identity rests on a parent whose own characterisation is not documented. Contrast AOD-9604, whose parent is an approved biologic, and LL-37, whose parent is a defined human gene product.

Sources

1. US FDA. Briefing document, Pharmacy Compounding Advisory Committee, evaluation of BPC-157-related bulk drug substances, 11 May 2026
2. US FDA. Meeting of the Pharmacy Compounding Advisory Committee, 23 and 24 July 2026
3. US FDA. Certain bulk drug substances for use in compounding that may present significant safety risks
4. World Anti-Doping Agency. 2026 Prohibited List, section S0
5. ClinicalTrials.gov. NCT02637284, phase 1 safety and pharmacokinetics

This page describes a compound as a material and summarises published research about it. It is for general and procurement information only. It is not medical advice, not a treatment recommendation, and not guidance on use. Supplied for laboratory and research use, not for human consumption.